Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:91:229-258.
doi: 10.1016/bs.apha.2021.01.003. Epub 2021 Mar 4.

Vaccines as therapies for food allergies

Affiliations

Vaccines as therapies for food allergies

Jeffrey J Landers et al. Adv Pharmacol. 2021.

Abstract

Food allergy is a growing public health epidemic with few available treatments beyond allergen avoidance and rescue medications for accidental exposures. A major focus of therapeutic development for food allergies is allergen-specific immunotherapy (AIT) in which patients are exposed to increasing amounts of allergen in controlled dosing to induce desensitization or tolerance. The work of the past few decades has culminated in the recent FDA approval of a peanut product for oral AIT for peanut allergies. Despite these advances, current AIT protocols are cumbersome, take a long time to reach clinical benefit and often have significant side effects. Therefore, there is a great need to develop new therapeutics for food allergy. One area of research aims to improve AIT through the use of adjuvants which are substances traditionally added to vaccines to stimulate or direct a specific immune response. Adjuvants that induce Th1-polarized and regulatory immune responses while suppressing Th2 immunity have shown the most promise in animal models. The addition of adjuvants to AIT may reduce the amount and frequency of allergen required to achieve clinical benefit and may induce more long-lasting immune responses. In this chapter, we highlight examples of adjuvanted AIT and vaccines in development to treat food allergies.

Keywords: Allergy treatment; Food allergy; Immunotherapy and tolerance induction; Immunotherapy vaccines and mechanisms; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest J.J.O. is an inventor on patent application that has been submitted for a nanoemulsion adjuvant for the suppression of allergic disease that is described in this chapter (PCT/US2015/054943). This technology has been licensed to Blue Willow Biologics, and the University of Michigan has a financial interest in Blue Willow Biologics. J.J.L. has no conflicts of interest to disclose.

Similar articles

Cited by

LinkOut - more resources